[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-349731-105":3,"detail-sidebar-cat-0-en-105":73,"doc-detail-349731-en":122},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":66,"head_meta":68,"extra_data":70,"updated_unix":72},105,"en","killing-cancer-takes-guts-lessons-learned-from-the-manipulation-of-gut-microbiome-and-immunotherapy-for-the-future-of-urothelial-carcinoma","Killing cancer takes guts - lessons learned from the manipulation of gut microbiome and immunotherapy for the future of urothelial carcinoma","","Urothelial carcinoma remains a prevalent cancer worldwide with substantial morbidity and mortality. Immune checkpoint inhibitors have transformed UC treatment, while evidence increasingly links gut microbiome composition to immune function and immunotherapy response. This review summarizes preclinical mechanisms, current interventions that modulate microbiome diversity, and clinical trials connecting microbiome changes to improved outcomes. It discusses microbial taxa, immune pathways, and the need for further studies to convert nonresponders into responders, especially for UC.",{"@graph":14,"@context":65},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/killing-cancer-takes-guts-lessons-learned-from-the-manipulation-of-gut-microbiome-and-immunotherapy-for-the-future-of-urothelial-carcinoma/349731/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/killing-cancer-takes-guts-lessons-learned-from-the-manipulation-of-gut-microbiome-and-immunotherapy-for-the-future-of-urothelial-carcinoma/349731.png","ImageObject",300,407,{"name":42,"@type":43},"Lucas Martin","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-06","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59],{"name":60,"@type":61,"acceptedAnswer":62},"How do interventions such as FMT, probiotics, or diet relate to immunotherapy outcomes?","Question",{"text":63,"@type":64},"FMT, probiotic supplementation, and dietary modulation are described as promising methods to alter microbiomes in ways that can improve immunotherapy outcomes, with evidence from preclinical studies and ongoing trials.","Answer","https://schema.org",{"og:url":32,"og:type":67,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":69,"canonical":32},"index,follow",{"doc_id":71,"site_id":7},349731,1790820624,{"code":4,"msg":74,"data":75},"success",[76,80,84,88,93,98,103,106,111,114,118],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":77,"show_sort_weight":78,"slug":79},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":81,"show_sort_weight":82,"slug":83},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Exam",70,"exam",{"id":89,"doc_module":4,"doc_module_name":25,"category_name":90,"show_sort_weight":91,"slug":92},5,"Comic",60,"comic",{"id":94,"doc_module":4,"doc_module_name":25,"category_name":95,"show_sort_weight":96,"slug":97},6,"Technology",50,"technology",{"id":99,"doc_module":4,"doc_module_name":25,"category_name":100,"show_sort_weight":101,"slug":102},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":104,"slug":105},30,"research-report",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},9,"Religion & Spirituality",20,"religion-spirituality",{"id":109,"doc_module":4,"doc_module_name":25,"category_name":112,"show_sort_weight":109,"slug":113},"World Cup","world-cup",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":115,"slug":117},10,"Lifestyle","lifestyle",{"id":119,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":89,"slug":121},19,"General","general",{"code":4,"msg":74,"data":123},{"doc_id":71,"user_id":124,"nickname":42,"user_avatar":125,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":126,"file_id":127,"file_url":128,"file_type":129,"file_size":130,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":131,"language":132,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":133,"faqs":134,"seo_title":135,"seo_description":12,"update_tm":136,"read_time":101,"preview_page_count":33,"preview_urls":137},8796095360427,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","REVIEW ARTICLE     \nKilling cancer takes guts: lessons learned from the manipulation of gut microbiome and immunotherapy for the future of urothelial carcinoma  \nNihaal Reddya , Kire Laua, Jacob Namana, Kevin Lua, Erin McGillivaryb, Amirali Salmasic, Michael Lissc and Tyler Stewartb  \naDepartment of Medicine, University of California, San Diego, CA, USA; bDepartment of Medicine, Division of HematologyOncology, University of California, San Diego, CA, USA; cDepartment of Urology, University of California, San Diego, CA, USA  \nABSTRACT  \nUrothelial carcinoma (UC) remains a common cancer with significant morbidity and mortality worldwide. Immune checkpoint inhibitors (ICIs) have helped revolutionize the treatment of UC, and there is growing evidence suggesting the crucial role of the gut microbiome in immune system function influences immunotherapy outcomes in this disease. Herein, we review the preclinical basis for how manipulation of the gut microbiome may alter the efficacy of immunotherapy for patients with cancer, highlight interventions optimizing gut microbiome diversity currently in use, review recent and ongoing clinical trials supporting the role of the gut microbiome in improving immunotherapy outcomes, and discuss clinical implications to improve outcomes for UC patients with immunotherapy in the real world. There is growing evidence that suggests that specific gut microbiome compositions significantly modulate the host immune system and response to ICIs. Early studies have shown that certain microbial taxa enhance antitumor immunity by influencing T cell priming, dendritic cell activation, and cytokine production. Fecal microbiota transplantation (FMT), probiotic supplementation, and dietary modulation have emerged as promising methods to alter microbiomes to improve immunotherapy outcomes. Taxa from positive immunotherapy responders across a variety of cancers demonstrate beneficial effects when transplanted into both treatment-naive or prior nonresponders. Increasing evidence suggests that the gut microbiome plays a crucial role in cancer care, particularly when patients are treated with immunotherapy. Future studies are needed to better understand the underlying mechanisms. While some studies are currently underway to explore gut manipulation for patients with UC, more studies are needed to investigate the potential to convert nonresponders into responders through microbiome manipulation.  \nARTICLE HISTORY  \nReceived 27 August 2025 Revised 19 December 2025 Accepted 27 December 2025  \nKEYWORDS  \nMicrobiome; immunotherapy; immuno-oncology; gut microbiome; urothelial carcinoma; immune checkpoint inhibitors; fecal microbiota transplantation  \nIntroduction  \nImmunotherapy has dramatically changed the treatment landscape for cancer, including urothelial carcinoma, and is now the standard of care for multiple lines of treatment for nearly all stages of bladder cancer. 1–4 The two most well-studied immunotherapy strategies in UC include monoclonal antibodies that inhibit programmed cell death 1 (PD-1) and cytotoxic T-lymphocyte antigen 4 (CTLA-4), which induce and enhance T cell-mediated immune responses against tumor-associated antigens.3–5 While some patients derive tremendous benefit, the majority of patients do not respond to immunotherapy. While several patient and tumor-specific factors contribute to responsiveness to ICI therapy, the relationship between the gut microbiome and anti-tumor has become an increased area of investigation.5–12  \nIntestinal microbiota are a complex system of diverse microorganisms including bacteria, protozoa, and viruses that live within host systems in a symbiotic fashion, playing an important role in digestion, metabolism, and immune function.6,7, 13 Current research has demonstrated the gut microbiome promotes antigen presentation, T cell activation and tumor infiltration, and direct cytotoxicity via enhancing molecular mimicry.6,8, 10, 13  \nCONTACT Tyler Stewart  [tstewart@health.uc","cbCaijMZCZQSui2l","https://ap.wps.com/l/cbCaijMZCZQSui2l","pdf",1325982,16,"English","# Introduction\n# Gut microbiome and immunotherapy rationale\n# Antibiotic-treated mice demonstrate impaired immunotherapy efficacy","[{\"question\":\"How do interventions such as FMT, probiotics, or diet relate to immunotherapy outcomes?\",\"answer\":\"FMT, probiotic supplementation, and dietary modulation are described as promising methods to alter microbiomes in ways that can improve immunotherapy outcomes, with evidence from preclinical studies and ongoing trials.\"}]","Killing cancer takes guts - lessons learned from the manipulation of gut microbiome and immunotherapy for the future of urothelial carcinoma | PDF",1790085290,[138,142,146,150],{"page_no":22,"url":139,"width":140,"height":141},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f0280d23db699fdbf360f28f8f6aae14.webp",983,1310,{"page_no":26,"url":143,"width":144,"height":145},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3e611b2db1064ff0956533584d593c55.webp",982,1309,{"page_no":30,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b81691254478d97843e530f2b2e1d27e.webp",981,1308,{"page_no":33,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b118c04d7bd9b6f0f6683ac41da621f8.webp",980,1306]